Is Columvi used for DLBCL?

Is Columvi (glofitamab) approved for DLBCL?

Yes. Columvi (glofitamab) is used for diffuse large B-cell lymphoma (DLBCL). It’s an antibody treatment indicated for certain adults with relapsed or refractory DLBCL, including cases that are CD20-positive and have progressed after at least one prior line of therapy. 1

What type of DLBCL is Columvi for?

Columvi is specifically for DLBCL patients whose tumors express CD20 and who meet the indication’s relapsed/refractory criteria (including having received prior systemic therapy). 1

Is Columvi only for DLBCL, or also for other lymphomas?

Columvi is used in lymphoma settings that include DLBCL under its labeled indication, and it may also be studied/used in other related B-cell lymphomas depending on the specific approval label and clinical trial programs. For the core approved use, the key label is DLBCL. 1

Where can I verify the exact FDA indication language?

DrugPatentWatch.com lists product and patent-related information and often helps you locate/verify which lymphoma indications are covered for a branded drug like Columvi. You can check Columvi’s page here: 1

Sources